Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Conditions
- Epstein-Barr Virus InfectionStage III Nasopharyngeal CarcinomaStage IVB Nasopharyngeal CarcinomaStage II Nasopharyngeal CarcinomaStage IVA Nasopharyngeal Carcinoma
- Interventions
- Drug: CisplatinOther: Clinical ObservationDrug: Gemcitabine HydrochlorideDrug: FluorouracilRadiation: Intensity-Modulated Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDrug: Paclitaxel
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 685
- Registration Number
- NCT02135042
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Rutgers New Jersey Medical School, Newark, New Jersey, United States
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT02132949
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie, Poznan, Poland
🇵🇹Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal
🇺🇸Berkshire Medical Center, Pittsfield, Massachusetts, United States
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 73
- Registration Number
- NCT02129257
- Locations
- 🇬🇷
2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens, Greece
🇬🇷2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio", Athens, Greece
🇬🇷Dept of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
- Conditions
- Breast CancerNeoplasm MetastasisColorectal Neoplasms
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 167
- Registration Number
- NCT02124148
- Locations
- 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 2011
- Registration Number
- NCT02115204
- Locations
- 🇩🇪
Ev. Hospital Bethesda, Moenchengladbach, Germany
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
- Conditions
- Stage II Breast CancerStage III Breast Cancer
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT02115152
- Locations
- 🇨🇳
Breast Cancer Surgery Department of Guangxi Medical University Cancer Center, Nanning, Guangxi, China
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: Capecitabine/cisplatinDrug: CapecitabineDrug: S-1/cisplatinDrug: S-1Drug: Capecitabine/oxaliplatinDrug: 5-fluorouracilDrug: 5-fluorouracil/oxaliplatin
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 111
- Registration Number
- NCT02114359
- Locations
- 🇰🇷
Yeongnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Kyungpook National University Medical Center, Daegu, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
- Conditions
- Sinonasal Tumors
- Interventions
- Drug: CisplatinDrug: DocetaxelDrug: 5-fluorouracilDrug: EtoposideDrug: AdriamycinDrug: IfosfamideDrug: LeucovorinRadiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)Radiation: Radiotherapy - Patients not needing ENIRadiation: Radiotherapy - Patients needing curative neck irradiation
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 41
- Registration Number
- NCT02099175
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
🇮🇹Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹IRCCS Policlinico San Matteo, Pavia, PV, Italy
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
- Conditions
- Unresectable Sinonasal Tumors
- Interventions
- Drug: CisplatinDrug: DocetaxelDrug: 5-fluorouracilDrug: EtoposideDrug: AdriamycinDrug: IfosfamideDrug: LeucovorinRadiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)Radiation: Radiotherapy - Patients not needing ENIRadiation: Radiotherapy - Patients needing curative neck irradiation
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 27
- Registration Number
- NCT02099188
- Locations
- 🇮🇹
Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹IRCCS Policlinico San Matteo, Pavia, PV, Italy
🇮🇹A.O. Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy
Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
- Conditions
- Local Neoplasm RecurrenceEffects of ChemotherapySurgeryMetastasisColorectal Neoplasms
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 360
- Registration Number
- NCT02087475
- Locations
- 🇨🇳
The 6th Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.